TB-500 vs Thymosin Alpha-1: Research Comparison | Regena

TB-500 is a synthetic peptide based on the active region of thymosin beta-4 (Tβ4). Its proposed research mechanism centres on the actin-binding axis — actin sequestration and downstream effects on cell migration, angiogenesis and tissue remodelling.

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide derived from prothymosin-α. Its proposed research mechanism centres on T-cell axis modulation — enhancement of T-cell maturation and downstream immune-response signalling in preclinical models.

TB-500 acts through the thymosin-β4 actin-binding axis rather than a conventional cell-surface receptor.

Thymosin Alpha-1 acts via Toll-like receptor pathways (TLR2 / TLR9) in the immune-axis research literature, with downstream effects on T-cell differentiation and cytokine-response programmes.

TB-500 is a longer peptide fragment with a research half-life supporting less-frequent-than-daily research cadences.

Thymosin Alpha-1 has a short pharmacokinetic half-life (approximately two hours in published research) and is typically used in twice-weekly research cadences in preclinical immune-axis models.

TB-500 is used in research models of cell migration, wound healing, angiogenesis and tissue remodelling.

Thymosin Alpha-1 is used in research models of immune-response modulation, T-cell axis studies, viral-response research and adjuvant immune-axis work.

Both TB-500 and Thymosin Alpha-1 ship from Regena only after independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds are published on the Regena lab reports page so a research-peptide buyer can audit the analytical detail before purchase. The /trust/how-to-read-a-coa reference walks through every field on a modern Regena COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a 28-day in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both TB-500 and Thymosin Alpha-1 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose TB-500 when the protocol targets the tissue-repair / actin-binding axis — cell migration, wound-healing, angiogenesis. Researchers choose Thymosin Alpha-1 when the protocol targets the immunomodulatory / T-cell axis. The two are complementary rather than substitutable — comparator studies sometimes include both to characterise thymosin-family effects across two independent research axes.

For multi-compound comparator studies, the Regena consultations team will reserve matched-batch inventory of both TB-500 and Thymosin Alpha-1 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Both TB-500 and Thymosin Alpha-1 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on the Regena site exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.